TITLE

The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases

AUTHOR(S)
Solary, E; Bernard, O A; Tefferi, A; Fuks, F; Vainchenker, W
PUB. DATE
March 2014
SOURCE
Leukemia (08876924);Mar2014, Vol. 28 Issue 3, p485
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Ten-Eleven Translocation-2 (TET2) inactivation through loss-of-function mutation, deletion and IDH1/2 (Isocitrate Dehydrogenase 1 and 2) gene mutation is a common event in myeloid and lymphoid malignancies. TET2 gene mutations similar to those observed in myeloid and lymphoid malignancies also accumulate with age in otherwise healthy subjects with clonal hematopoiesis. TET2 is one of the three proteins of the TET (Ten-Eleven Translocation) family, which are evolutionarily conserved dioxygenases that catalyze the conversion of 5-methyl-cytosine (5-mC) to 5-hydroxymethyl-cytosine (5-hmC) and promote DNA demethylation. TET dioxygenases require 2-oxoglutarate, oxygen and Fe(II) for their activity, which is enhanced in the presence of ascorbic acid. TET2 is the most expressed TET gene in the hematopoietic tissue, especially in hematopoietic stem cells. In addition to their hydroxylase activity, TET proteins recruit the O-linked β-D-N-acetylglucosamine (O-GlcNAc) transferase (OGT) enzyme to chromatin, which promotes post-transcriptional modifications of histones and facilitates gene expression. The TET2 level is regulated by interaction with IDAX, originating from TET2 gene fission during evolution, and by the microRNA miR-22. TET2 has pleiotropic roles during hematopoiesis, including stem-cell self-renewal, lineage commitment and terminal differentiation of monocytes. Analysis of Tet2 knockout mice, which are viable and fertile, demonstrated that Tet2 functions as a tumor suppressor whose haploinsufficiency initiates myeloid and lymphoid transformations. This review summarizes the recently identified TET2 physiological and pathological functions and discusses how this knowledge influences our therapeutic approaches in hematological malignancies and possibly other tumor types.
ACCESSION #
94762947

 

Related Articles

  • Granulocytes Affect Double-Strand Break Repair Assays in Primary Human Lymphocytes. Lacoste, Sandrine; Bhatia, Ravi; Bhatia, Smita; O'Connor, Timothy R. // PLoS ONE;Mar2014, Vol. 9 Issue 3, p1 

    Patients who develop therapy-related myelodysplasia/acute myeloid leukemia after autologous-hematopoietic stem cell (aHCT) transplant show lower expression levels of DNA repair genes in their pre-aHCT CD34+ cells. To investigate whether this leads to functional differences in DNA repair...

  • Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia. Kharas, Michael G.; Lengner, Christopher J.; Al-Shahrour, Fatima; Bullinger, Lars; Ball, Brian; Zaidi, Samir; Morgan, Kelly; Tam, Winnie; Paktinat, Mahnaz; Okabe, Rachel; Gozo, Maricel; Einhorn, William; Lane, Steven W.; Scholl, Claudia; Fröhling, Stefan; Fleming, Mark; Ebert, Benjamin L.; Gilliland, D. Gary; Jaenisch, Rudolf; Daley, George Q. // Nature Medicine;Aug2010, Vol. 16 Issue 8, p903 

    RNA-binding proteins of the Musashi (Msi) family are expressed in stem cell compartments and in aggressive tumors, but they have not yet been widely explored in the blood. Here we demonstrate that Msi2 is the predominant form expressed in hematopoietic stem cells (HSCs), and its knockdown leads...

  • Regulation of the Flt3 Gene in Haematopoietic Stem and Early Progenitor Cells. Volpe, Giacomo; Clarke, Mary; Garcìa, Paloma; Walton, David Scott; Vegiopoulos, Alexandros; Del Pozzo, Walter; O’Neill, Laura Patricia; Frampton, Jonathan; Dumon, Stéphanie // PLoS ONE;9/18/2015, Vol. 10 Issue 9, p1 

    The MYB transcription factor plays critical roles in normal and malignant haematopoiesis. We previously showed that MYB was a direct activator of FLT3 expression within the context of acute myeloid leukaemia. During normal haematopoiesis, increasing levels of FLT3 expression determine a strict...

  • Requirement for CD44 in homing and engraftment of BCR-ABL–expressing leukemic stem cells. Krause, Daniela S.; Lazarides, Katherine; von Andrian, Ulrich H.; Van Etten, Richard A. // Nature Medicine;Oct2006, Vol. 12 Issue 10, p1175 

    In individuals with chronic myeloid leukemia (CML) treated by autologous hematopoietic stem cell (HSC) transplantation, malignant progenitors in the graft contribute to leukemic relapse, but the mechanisms of homing and engraftment of leukemic CML stem cells are unknown. Here we show that CD44...

  • Zebrafish as a Model for the Study of Human Myeloid Malignancies. Lu, Jeng-Wei; Hsieh, Meng-Shan; Liao, Heng-An; Yang, Yi-Ju; Ho, Yi-Jung; Lin, Liang-In // BioMed Research International;5/3/2015, Vol. 2015, p1 

    Myeloid malignancies are heterogeneous disorders characterized by uncontrolled proliferation or/and blockage of differentiation of myeloid progenitor cells. Although a substantial number of gene alterations have been identified, the mechanism by which these abnormalities interact has yet to be...

  • Allogeneic hematopoietic cell transplant for normal karyotype AML: indirect evidence of selection for adverse molecular profile. Percival, M-E M; Medeiros, B C; Tian, L; Robeson, S; Laport, G G; Johnston, L J; Shizuru, J A; Miklos, D B; Arai, S; Weng, W-K; Negrin, R S; Lowsky, R // Bone Marrow Transplantation;Jul2015, Vol. 50 Issue 7, p1004 

    A letter to the editor is presented which discusses the potential of allogeneic hematopoietic cell transplantation in the treatment of normal karyotype acute myeloid leukemia (AML).

  • Membrane Tyrosine Kinase Receptors are an Important Target for the Therapy of Acute Myeloid Leukemia. Testa, Ugo // Current Cancer Therapy Reviews;2008, Vol. 4 Issue 1, p31 

    KIT and FLT3 are class III trans membrane tyrosine kinases playing key roles in the control of hematopoietic stem cell survival and proliferation. KIT is mutated in about 2.5-3% of acute myeloid leukemia (AML) patients mainly by point mutations occurring at the level of tyrosine kinase domains....

  • MiR-125 in normal and malignant hematopoiesis. Shaham, L; Binder, V; Gefen, N; Borkhardt, A; Izraeli, S // Leukemia (08876924);Sep2012, Vol. 26 Issue 9, p2011 

    MiR-125 is a highly conserved microRNA throughout many different species from nematode to humans. In humans, there are three homologs (hsa-miR-125b-1, hsa-miR-125b-2 and hsa-miR-125a). Here we review a recent research on the role of miR-125 in normal and malignant hematopoietic cells. Its high...

  • Hematopoietic stem cell-independent hematopoiesis: emergence of erythroid, megakaryocyte, and myeloid potential in the mammalian embryo. Palis, James // FEBS Letters;Nov2016, Vol. 590 Issue 22, p3965 

    Steady-state production of all circulating blood cells in the adult ultimately depends on hematopoietic stem cells ( HSCs), which first arise in small numbers beginning at embryonic day (E) 10.5 in large arterial vessels of the murine embryo. However, blood cell synthesis first begins in the...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics